FDA Relaxing Restrictions on GSK’s Controversial Diabetes Drug Avandia

Washington Drug Letter
A A
Three years after placing heavy restrictions on GlaxoSmithKline’s type 2 diabetes drug Avandia, the FDA said Nov. 25 it is relaxing those restrictions in line with its advisers’ recommendations.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00